Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Inventory (2017 - 2025)

Historic Inventory for Neurocrine Biosciences (NBIX) over the last 8 years, with Q4 2025 value amounting to $69.0 million.

  • Neurocrine Biosciences' Inventory rose 2020.91% to $69.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $69.0 million, marking a year-over-year increase of 2020.91%. This contributed to the annual value of $69.0 million for FY2025, which is 2020.91% up from last year.
  • As of Q4 2025, Neurocrine Biosciences' Inventory stood at $69.0 million, which was up 2020.91% from $69.3 million recorded in Q3 2025.
  • Neurocrine Biosciences' 5-year Inventory high stood at $69.3 million for Q3 2025, and its period low was $25.5 million during Q3 2021.
  • Over the past 4 years, Neurocrine Biosciences' median Inventory value was $38.3 million (recorded in 2023), while the average stood at $43.6 million.
  • The largest annual percentage gain for Neurocrine Biosciences' Inventory in the last 5 years was 5902.78% (2024), contrasted with its biggest fall of 1137.72% (2024).
  • Neurocrine Biosciences' Inventory (Quarter) stood at $25.5 million in 2021, then surged by 50.2% to $38.3 million in 2023, then surged by 49.87% to $57.4 million in 2024, then grew by 20.21% to $69.0 million in 2025.
  • Its Inventory stands at $69.0 million for Q4 2025, versus $69.3 million for Q3 2025 and $56.9 million for Q2 2025.